- Home
- FFA vs CELC Comparison
FFA vs CELC Comparison
Compare FFA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- CELC
- Stock Information
- Founded
- FFA 2004
- CELC 2011
- Country
- FFA United States
- CELC United States
- Employees
- FFA N/A
- CELC N/A
- Industry
- FFA Investment Managers
- CELC Medical Specialities
- Sector
- FFA Finance
- CELC Health Care
- Exchange
- FFA Nasdaq
- CELC Nasdaq
- Market Cap
- FFA 416.6M
- CELC 489.7M
- IPO Year
- FFA N/A
- CELC 2017
- Fundamental
- Price
- FFA $20.60
- CELC $12.38
- Analyst Decision
- FFA
- CELC Strong Buy
- Analyst Count
- FFA 0
- CELC 6
- Target Price
- FFA N/A
- CELC $29.17
- AVG Volume (30 Days)
- FFA 26.1K
- CELC 232.9K
- Earning Date
- FFA 01-01-0001
- CELC 11-14-2024
- Dividend Yield
- FFA 6.72%
- CELC N/A
- EPS Growth
- FFA N/A
- CELC N/A
- EPS
- FFA N/A
- CELC N/A
- Revenue
- FFA N/A
- CELC N/A
- Revenue This Year
- FFA N/A
- CELC N/A
- Revenue Next Year
- FFA N/A
- CELC N/A
- P/E Ratio
- FFA N/A
- CELC N/A
- Revenue Growth
- FFA N/A
- CELC N/A
- 52 Week Low
- FFA $15.84
- CELC $11.51
- 52 Week High
- FFA $19.30
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- FFA 50.14
- CELC 42.58
- Support Level
- FFA $20.92
- CELC $11.94
- Resistance Level
- FFA $21.14
- CELC $13.14
- Average True Range (ATR)
- FFA 0.19
- CELC 0.51
- MACD
- FFA -0.04
- CELC 0.07
- Stochastic Oscillator
- FFA 0.00
- CELC 58.70
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.